Dr.Β EdwardΒ Kim
BS, MD, MBA, FACP, FASCO
Physician-in-Chief, City of Hope Orange County
corporate_fareCity of Hope Cancer Center, Irvine, California
Edward Kim
BS, MD, MBA, FACP, FASCO
Professor Edward S. Kim is a world-renowned medical oncologist and physician executive serving as Physician-in-Chief at City of Hope Orange County Lennar Foundation Cancer Center in Irvine, California, and Vice Physician-in-Chief at City of Hope National Medical Center in Duarte, California. He is an internationally recognised expert in thoracic oncology, with over 22 years of clinical and research experience in lung cancer, head and neck cancer, and thyroid cancer.
Prof. Kim trained at Northwestern University (BS 1992, MD 1996), completed his internal medicine residency at Baylor College of Medicine, and his medical oncology fellowship at MD Anderson Cancer Center. He spent a decade at MD Anderson as Tenured Associate Professor and Chief of the Section of Head and Neck Medical Oncology before leading solid tumour oncology at Levine Cancer Institute, Atrium Health, from 2012 to 2020. He is the lead investigator of the landmark BATTLE trial β the first prospective, biopsy-mandated, biomarker-based, adaptively randomised lung cancer study β which established a new paradigm for personalised cancer therapy. He has authored over 250 published articles in journals including The Lancet, Journal of Clinical Oncology, Cancer Discovery, and Nature Medicine, and earned his MBA from UNC Kenan-Flagler Business School in 2020. Recognised as a U.S. News & World Report Top Doctor and a Modern Healthcare Top Diversity Leader, Prof. Kim is a board member of Friends of Cancer Research and a committed advocate for equity in clinical trial participation.
City of Hope provides comprehensive services for international patients. CancerFax can coordinate medical-record review, second opinion requests, and consultation support with Prof. Kim's team, subject to hospital availability.
Why Consider Prof. Edward S. Kim?
Prof. Kim combines deep scientific expertise in molecular oncology with more than two decades of clinical leadership at America's top cancer institutions, offering patients access to personalised, research-driven lung and head and neck cancer care.
Areas of Specialisation
Thoracic oncology, head and neck cancer, and biomarker-guided precision therapy
Prof. Kim's clinical focus spans lung cancer, head and neck cancer, and thyroid cancer, with a research emphasis on molecular prognostication and biomarker-integrated treatment strategies for solid tumours.
Lung Cancer (Thoracic Oncology)
Comprehensive medical oncology for non-small cell lung cancer and other thoracic malignancies, with a focus on biomarker-guided, personalised treatment planning.
- arrow_rightBiomarker-integrated treatment planning following molecular profiling
- arrow_rightEGFR-targeted therapy (erlotinib, vandetanib) for eligible patients
- arrow_rightKRAS-targeted approaches (sorafenib) where applicable
- arrow_rightImmunotherapy selection based on PD-L1 and tumour mutational burden
- arrow_rightAdaptive, biopsy-mandated therapy selection based on tumour biology
- arrow_rightNovel combination and non-cytotoxic regimens for advanced disease
- arrow_rightPhase I/II investigational agent protocols via clinical trials
Head & Neck Oncology
Expert medical oncology management of head and neck cancers including malignant thymoma, with experience from a decade leading the Section of Head and Neck Medical Oncology at MD Anderson.
- arrow_rightSystemic therapy for squamous cell carcinomas of the head and neck
- arrow_rightCetuximab-based regimens in eligible patients
- arrow_rightMultidisciplinary induction chemotherapy for unresectable malignant thymomas
- arrow_rightIntegration of targeted and immunotherapy approaches
- arrow_rightMedical oncology management of advanced thyroid malignancies
- arrow_rightTargeted therapy for radioiodine-refractory thyroid cancer
Molecular Prognostication & Clinical Trials
Pioneering work in translating molecular findings into clinical treatment decisions, with principal investigator roles across landmark lung cancer and solid tumour trials.
- arrow_rightBiomarker-based risk stratification for lung and head and neck cancers
- arrow_rightAdvancing cancer detection through translational research
- arrow_rightEGFR, KRAS, and other driver mutation-guided therapy selection
Procedures & Treatment Approaches
Personalised systemic therapy, investigational agents, and multidisciplinary care
Prof. Kim offers a comprehensive range of medical oncology services at City of Hope, with a strong emphasis on precision oncology and clinical trial access for patients with lung cancer, head and neck cancer, and other thoracic malignancies.
Personalised Medical Oncology
Medical OncologyBiomarker-guided systemic therapy planning and administration for lung cancer and head and neck cancer.
Targeted Therapy
Targeted TherapyMolecularly guided targeted treatment for eligible patients with actionable driver mutations.
Clinical Trial Access
Complex DiseasePrincipal and co-principal investigator roles on landmark trials, providing eligible patients access to investigational therapies including the pioneering BATTLE trial programme.
Multidisciplinary Treatment Planning
MultidisciplinaryTeam-based cancer care at City of Hope involving oncology, surgery, radiation, pathology, and supportive disciplines.
Second Opinion Services
Second OpinionIndependent expert review of pathology, molecular profiling, and existing treatment plans for lung cancer and head and neck cancer patients.
Research & Publications
Over 250 peer-reviewed publications and landmark clinical trial leadership
Prof. Kim is one of the most prolific clinical researchers in thoracic oncology, with over 250 published articles in top-tier journals. His research centres on molecular prognostication, biomarker-integrated targeted therapy, personalised medicine for lung cancer, and equity in clinical trial participation.
Prof. Kim's active clinical trial programme at City of Hope means eligible patients may have access to investigational agents. CancerFax can assess your case and coordinate the enquiry with City of Hope's research team.
Education & Training
Prof. Kim completed his undergraduate and medical training at Northwestern University through its prestigious Honors Program in Medical Education, followed by advanced postgraduate training at Baylor College of Medicine and MD Anderson Cancer Center.
Clinical Experience
Prof. Kim's career spans more than two decades at America's leading cancer institutions, from a decade at MD Anderson Cancer Center to senior leadership roles at Levine Cancer Institute and now as Physician-in-Chief at City of Hope Orange County.
Languages & International
Prof. Kim conducts consultations in English.
CancerFax coordinates certified medical interpreters for patients who require support in languages other than English.
CancerFax can coordinate professional medical interpreter support for international patients consulting in other languages.
How CancerFax Helps You Access Dr. Edward Kim
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Edward Kim's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Edward Kim's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Edward Kim before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Edward Kim's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Edward Kim's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Edward Kim's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Edward S. Kim
Prof. Kim specialises in lung cancer (non-small cell lung cancer, NSCLC), head and neck cancer (including squamous cell carcinomas and malignant thymoma), and thyroid cancer. He also treats oesophageal cancer and other thoracic malignancies.
The BATTLE (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial was the first completed prospective, biopsy-mandated, biomarker-based, adaptively randomised study in lung cancer. Led by Prof. Kim at MD Anderson Cancer Center, it established a new paradigm for personalised lung cancer therapy by matching treatment to each patient's tumour biology rather than using a one-size-fits-all approach.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your documents, prepare a structured case summary, and coordinate the consultation request with City of Hope, subject to availability. We handle all pre-consultation logistics.
City of Hope provides international patient services, and CancerFax can coordinate medical-record review, second opinion requests, and consultation support for patients outside the United States seeking access to Prof. Kim's expertise. The final consultation format and availability are subject to City of Hope's international patient programme terms.
Prof. Kim offers biomarker-guided precision oncology including EGFR-targeted therapy (erlotinib, vandetanib), KRAS-targeted approaches (sorafenib), cetuximab-based regimens for head and neck cancers, immunotherapy, chemotherapy, and novel investigational combination therapies through clinical trials. Treatment is selected based on molecular profiling of the patient's tumour.
Yes. Prof. Kim has been a principal or co-principal investigator on numerous landmark clinical trials, including the BATTLE trial and multiple SWOG cooperative group studies. He continues to lead and participate in clinical research at City of Hope. CancerFax can help assess your eligibility for open trials as part of the consultation coordination process.
Prof. Kim holds an MD from Northwestern University, an MBA from UNC Kenan-Flagler Business School, and is board-certified in Internal Medicine and Medical Oncology. He is a Fellow of the American College of Physicians (FACP) and Fellow of the American Society of Clinical Oncology (FASCO). He has been named a U.S. News & World Report Top Doctor and a Modern Healthcare Top Diversity Leader in Healthcare in both 2021 and 2023.
Connect with Edward Kim Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.